The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

Background Teriflunomide is a new oral disease-modifying therapy for relapsing forms of
multiple sclerosis. Methods We concluded a randomized trial involving 1088 patients with …

Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has
demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). …

Objective To determine to what degree changes in retinal nerve fiber layer (RNFL) thickness
after optic neuritis (ON) correlate with either visual recovery or impairment. Methods ON can …

New criteria for the diagnosis of multiple sclerosis (MS) were published as the result of an
internationally formed committee. To increase the specificity of diagnosis and to minimize the …

Background Several controlled studies provide evidence that treatment with interferon beta
in patients with a first event suggestive of multiple sclerosis (MS) delays conversion to …

Background Teriflunomide is an oral disease-modifying therapy approved for treatment of
relapsing or relapsing–remitting multiple sclerosis. We aimed to provide further evidence for …

Importance It remains unclear whether vitamin D insufficiency, which is common in
individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. Objectives To …

Background No treatments have been approved for primary progressive multiple sclerosis.
Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-…